Problem: How maternal allergy affects the systemic and local immunological environment during pregnancy and the immune development of the offspring is unclear.
Introduction
Pregnancy and allergic disease have both been postulated as T-helper (Th) 2 phenomena, since Th2-associated cytokines are present at the feto-maternal interface 1 and the same cytokines are induced in response to allergens. [2] [3] [4] The combination of these two states, i.e.
allergic and pregnant, has been associated with favorable effects on the maintenance of pregnancy, namely, longer gestational age, higher birth weight and length, [5] [6] [7] lower risk of pre-term birth 8 and shorter waiting time to achieve pregnancy. 9 Thus, maternal allergy could constitute an evolutionary benefit. From a clinical perspective, it is not settled whether pregnancy influences the severity of maternal allergy symptoms, which may be due to several confounding factors occurring during pregnancy. 10 However, the idea of magnified Th2 responses during pregnancy in allergic women is supported by the observation of increased total IgE levels during pregnancy as compared to after delivery in allergic women, 11 the association of maternal allergy and reduced IFN-γ production to fetal and paternal alloantigens [12] [13] [14] and a lack of down-regulation of allergen-induced IL-13 secretion in late gestation. 15 The increased propensity of allergic mothers to mount Th2-responses could, on one hand, be regarded as favorable for pregnancy, but on the other hand, be regarded as unfavorable, as fetal exposure to a strong Th2 environment could influence the immune development in the offspring to a Th2-associated phenotype favouring IgE production and possibly allergy development later in life. 16 Accordingly, children of allergic mothers have shown increased cord blood (CB) IgE levels as compared with children with allergic fathers or children with two non-allergic parents. [17] [18] [19] [20] Furthermore, maternal IgE levels during pregnancy correlated with CB IgE and the Th2-associated chemokine CCL22 levels. 21 In addition, maternal IgE levels in late gestation predicted the offspring's IgE levels at birth and at 1 year of age. 22 The importance of the Th1/Th2 profile at birth for allergy development later in life has been characterized by our group 21, 23, 24 and by others. 25, 26 Increased CCL17 and CCL22 levels at birth were associated with development of allergic symptoms and sensitization during the first 2, 21, 24 3 25 and 6 years of life. 23 Also, questionnaire-reported wheezing during infancy was preceded by high CB CCL22 levels. 26 The impact of maternal allergy on local and systemic gene expression during pregnancy and the fetal immune development, is not understood. In fact, the immunological environment in the placental tissue, including cells of fetal origin, has not been previously characterized in normal pregnancies in relation to maternal allergy status.
We aimed to assess the systemic and local gene expression during pregnancy in allergic and non-allergic mothers and the immunological interactions between mother and child by analyzing expression of 40 selected Th1-, Th2-, regulatory T-cells (Treg-) and Th17-associated genes in placenta, mononuclear cells derived from peripheral blood (PBMC) and cord blood (CBMC). This novel study design with paired PBMC and placenta samples gives us the opportunity to characterize gene expression profiles locally and systemically during pregnancy, as well as their potential association with fetally derived gene expression in CBMC. Further, the importance of early priming of the fetal immune system was assessed by analyzing gene expression in CBMC in relation to allergy development during childhood. We hypothesized that the immune profile in placenta, PBMC and CBMC is biased towards a Th2-associated profile in the allergic as compared with the non-allergic mothers and that allergy development in the offspring is preceded by a pronounced Th2-profile at birth.
Materials and methods

Study group
This study included 19 pregnant women from the Linköping area, County of Östergötland, Sweden (Fig 1) , who participated in a longitudinal study from early gestation to 1 year post-
partum. An experienced allergy research nurse interviewed the women regarding their allergic status. Seven women reported allergic symptoms (allergic rhinoconjuntivitis, ARC, n=7 of whom 1 woman also had eczema, primiparous n=3, parous n=4) and allergic sensitization was confirmed by the Phadiatop test (Phadia, Uppsala, Sweden The children of the women described above were followed prospectively from birth up to 6 years of age with questionnaires and clinical examinations at 6 and 12 months of age by an experienced allergy research nurse and at 24 months and 6 years of age by a paediatric allergologist. 23 The definition of atopic dermatitis (AD) was pruritic, chronic or chronically relapsing non-infectious dermatitis with typical features and distribution. Asthma bronchiale (AB), at 2 years of age, was defined as three or more episodes of bronchial obstruction at least once verified by a physician. A diagnosis of AB at 6 years of age required one or more episodes of bronchial obstruction after two years of age, at least once verified by a physician.
ARC was defined as seasonal itching and running eyes and nose, at least 2 times after 7 exposure of an inhalant allergen and no signs of infection. Urticaria was defined as allergic if it appeared within one hour after allergen exposure, at least at two separate occasions. A diagnosis of food allergy required vomiting and/or diarrhoea, hives, aggravated eczema or wheezing on at least two separate occasions after ingestion of certain offending food. Oral allergy syndrome was defined as allergic if it appeared at least at two separate occasions after ingestion of certain offending food.
Skin prick tests (SPT) were performed with standardized allergen extracts from Allergologisk Laboratorium A/S, (ALK, Soluprick®, Hørsholm, Denmark), i.e. egg white, milk (6, 12, 24 months and 6 years), cat (12, 24 months, 6 years), and birch and timothy (24 months and 6 years). Histamine hydrochloride (10 mg/ml) was used as positive control, albumin diluent (ALK) as a negative control and the cut off for positivity was when the mean wheal diameter was at least 3 mm. The allergen specific IgE concentrations to food and inhalant allergens (PhadiatopInfant test, Phadia, Uppsala, Sweden) were determined at 6, 12, 24 months and 6 years and inhalant allergens (Phadiatop test, Phadia) at 6 years of age using ImmunoCAP (Pharmacia Diagnostics, Uppsala, Sweden). The cut-off for positivity was 0.35 kU A /l for both tests.
CBMC from ten sensitized children with allergic symptoms and 6 non-sensitized children without allergic symptoms were added to allow assessment of gene expression of some selected genes (T-box expressed in T-cells (Tbx21), GATA binding protein 3 (GATA3), Forkhead box p3 (Foxp3), RAR-related orphan receptor C (RORC)) in relation to allergy development during childhood. Five of these 16 children were included in the original longitudinal study, i.e. they were followed to 6 years of age as described above (Fig 1) . The other 11 children were participating in a randomized placebo-controlled allergy prevention study based on omega 3 long-chain polyunsaturated fatty acid supplementation during pregnancy. 27 These 11 children were selected from the placebo group based on their attendance to the clinical examination at 8 years of age and the availability of CBMC. One of these 11 children was followed up to 2 years only; this child was sensitized to egg and wheat and diagnosed with AB, AD and food allergy at 2 years of age. 27 The SPT and the clinical follow ups were performed by the same research nurse for both study cohorts.
Taken together, 14 children who developed (described in detail in Table I ), and 13 children who did not develop allergic symptoms and sensitization during childhood were included. All children with allergic symptoms showed SPT reactivity and sensitization according to the presence of allergen specific IgE antibodies in the circulation. All children without allergic symptoms were SPT negative and the levels of allergen specific IgE antibodies in the circulation were below the cut-off for positivity.
Collection and preparation of CBMC, PBMC and placenta samples
Venous blood samples were drawn into heparin-treated tubes (Vacuette, Greiner Labortechnik, Kremsmünster, Austria). The cord blood samples were collected by cutting the umbilical cord at the placental site, carefully cleaning it to avoid contamination of maternal blood, and then squeezing it to collect the cord blood in heparin-treated tubes (Vacuette). The PBMC/CBMC were isolated and frozen as previously described, 28, 29 with an exception for the CBMC preparations; 2 volumes of RPMI-1640 (Life Technologies, Täby, Sweden) was added instead of 1 volume after plasma removal.
The placenta samples were collected at birth by cutting a cube, approximately 1x1x1 cm in size on the maternal side of the placenta, using a scalpel. The placental tissue was transferred to a sterile tube, frozen and stored at -70º C.
Seven PBMC and 6 paired placenta samples were collected from the allergic women together with 6 CBMC samples of whom 6 were paired with the PBMC samples and 5 with the placenta samples. Nine PBMC and 11 placenta samples (8 paired) were collected from the non-allergic women, and 8 CBMC samples of whom 5 were paired with the PBMC samples and 6 with the placenta samples. Sixteen CBMC samples (of whom 1 also was analyzed by PCR array), without paired PBMC or placenta samples were also included for the additional quantification of CCL22, Tbx21, GATA3, Foxp3 and RORC using real-time PCR (Fig1).
RNA extraction
The PBMC and CBMC were rapidly thawed in a 37 º C water bath and immediately lysed 
Reverse transcription PCR and real-time PCR
The RT 2 First Strand Kit (Qiagen) was used for reverse transcription of 1 µg total RNA from the CBMC samples and 0.69 µg total RNA from the PBMC and placenta samples, according to the manufacturer's instructions. Briefly, the RNA was treated with DNase at 42º C for 5 minutes (min) and then reversely transcribed into cDNA (42º C for 15 min followed by 95º C for 5 min) in a GeneAmp ® PCR System 2700 (Applied Biosystems Foster City, CA, USA).
The cDNA was mixed with RNase free water (Qiagen) and RT 2 SYBR ® Green Mastermix Forty genes (Table II) The mRNA expression of CCL22, YWHAZ (placenta, PBMC, CBMC samples), the T-cellassociated transcription factors Tbx21, GATA3, Foxp3, RORC and CD3ε (CBMC samples) was also quantified separately, due to suspected primer-dimer formation for CCL22 on the PCR array, and due to additional analysis of the transcription factors in CBMCs using an extended material of children. The 7900HT Fast Real-Time PCR System was used with the following thermal cycling conditions: 50º C for 2 min followed by 95º C for 10 min and then unpublished data). The mRNA levels of CD3ε were, as expected, increased in PBMC as compared to placental tissue (data not shown).
Statistics
The 
Results
Characterization of gene expression locally and systemically during pregnancy
Increased gene expression of GATA3, IL-5, IL-10, IL-33, CCL18, epstein-barr virus induced 3 (EBI3), indoleamine 2,3-dioxygenase 1 (IDO1), triggering receptor expressed on myeloid cells 2 (TREM2) and p40 was observed in the placenta samples as compared with the PBMC samples (Fig 2) . The 40 genes included in the PCR array (of whom CCL22 was quantified separately by a real-time PCR assay) with accompanying reference sequence number, description and the number of samples with detectable levels of the genes in the placenta, PBMCs and CBMCs are presented in Table II (Table III) .
Gene expression in placenta, PBMCs and CBMCs in relation to allergy in mother and child
Allergic women showed higher expression of p40 in placenta (p=0.01), p35 in PBMCs (p=0.02) and p35 in CBMCs (p=0.01) than non-allergic women. ΔCt values (median, range) for all genes in the placenta, PBMC and CBMC samples from allergic and non-allergic women are presented in Appendix II.
T-cell-associated gene expression (as normalized by using CD3ε) of the CBMC population showed increased GATA3 (Th2) and RORC (Th17) expression, respectively, in children who 16 developed allergy (n=4) as compared with children who did not (n=5, p=0.01 for both comparisons). Therefore, the transcription factors Tbx21, GATA3, Foxp3 and RORC (associated with Th1-, Th2-, Treg-, Th17-immunity, respectively) and the Th2-associated chemokine CCL22 were selected for additional analysis of mRNA expression in CBMCs in an extended material of children developing allergy (n=13) or not (n=11). CCL22 was selected due to our previous finding of increased CB CCL22 protein levels preceding allergy development. 21, 23 Corroborating our previous results, increased gene expression of CCL22
was observed already at birth in children later developing allergy as compared with children who did not (Fig 3) . Gene expression of the 4 transcription factors (Tbx21, GATA3, Foxp3
and RORC) was not related to allergy development in the extended cohort.
Gene expression in CBMCs was analyzed with gender as a potential confounding factor (Mann-Whitney U-test) for the initial and extended groups. Girls had a higher expression of IL-13 at birth than boys (p=0.03).
Discussion
The present study indicates a transcription profile dominated by Th2-and anti-inflammatory genes in the placenta, as compared with maternal PBMCs, irrespectively of maternal allergy, and an interplay between genes expressed locally and systemically during pregnancy and the fetal immunity at birth. The inverse relationship between placental p35 and fetal Tbx21 possibly indicates suppressive properties of placental p35, speculatively by IL-35, on the fetal Th1-like immunity. p35 can pair with p40 and EBI3, forming either pro-inflammatory IL-12(p70) or anti-inflammatory IL-35, but none of these subunits were correlated with fetal Tbx21 or placental p35 expression. One should keep in mind that the p35 protein is thought to be secreted with a partner and exerts its biological activities as a heterodimer. 31 In addition, the maternal systemic IL-5 expression during pregnancy was associated with fetal gene expression as well, as it correlated with fetal galectin1. Galectin1 is, besides being a β-galactosidase binding protein, suggested to be important for immune regulation including apoptosis and immune suppression, 32 but also for tissue remodelling including placenta development and angiogenesis. 33 Even though mRNA levels do not necessarily reflect protein levels in various tissues, our data suggest that immunological mediators in the local and cells in humans, reviewed in. 37 We acknowledge the limitation of studying gene expression, as mRNA levels do not properly reflect protein levels. The probability level of p<0.001 was selected for the correlation analyses after careful consideration, as an approach to adjust for the multiple correlation analyses, i.e. to reduce the frequency of type II errors. The results were always interpreted with caution, but we cannot completely exclude the possibility of reported false positive findings.
An enhanced placental Th2-shift of allergic mothers has been suggested to explain the higher risk for allergy development in children of allergic mothers versus fathers. 19, 20 The present study was not able to confirm such a relationship by studying mRNA expression in the placenta, but one should keep in mind that many important Th2 markers (IL-4, IL-9, IL-13, CCL11, CCL17, CCL22) were undetectable in the majority of samples. Thus, expression of Th2-associated genes could be increased in allergic women, but due to methodological limitations, impossible to detect. Expression of genes associated with Th2-and regulatory immune responses were increased in the placenta as compared with PBMC, regardless of the allergic status of the mother, suggesting that a strict immune regulation may be essential to prevent pregnancy complications. Allergy development during childhood was preceded by increased expression of the Th2-associated chemokine CCL22 at birth, indicating that the Th2-skewed immunity associated with allergic disease is established very early in life. This observation is in line with previous findings in this study cohort, as the protein levels of CCL22 were increased in CB plasma in children developing allergic symptoms and sensitization. 21, 23 Furthermore, chemokine levels at birth and during childhood were associated with maternal chemokine levels at various time points during pregnancy, supporting an interplay between maternal and fetal immunity. 40 More studies on the fetal immunity at birth in relation to prenatal allergy development, using other markers for Th1-, Th2-, Treg-and Th17-immunity, would be most welcome and constitute a valuable addition to this area of research.
In summary, placental gene expression, including cells of fetal origin, was dominated by a Samples with Ct >35 were given a ΔCt value of 16 for genes from the PCR array and 9 for genes from the real-time PCR assays (CCL22). Statistically significant differences in gene expression between allergic and non-allergic women are indicated in bold.ψ = Excluded due to suspected primer-dimer formation. CBMC = cord blood mononuclear cells, Ct = threshold cycle, PBMC = peripheral blood mononuclear cells The clinical examinations were performed at 6 years for the children in the upper half of the table (number 1-6) and at 8 years of age for the children in the lower half, (number 7-14).
All children with positive SPT were also sensitized according to the presence of allergen specific IgE antibodies in the circulation. Definition of abbreviations: AD = atopic dermatitis, AB = asthma bronchiale, ARC = allergic rhinoconjunctivitis, U = urticaria, FA = Food Allergy, SPT = skin prick test. ϕ =mostly associated with anti-inflammatory functions, ψ = This gene was excluded due to suspected primer-dimer formation. CCL22 was quantified using a TaqMan ® Gene Expression assay. CBMC = cord blood mononuclear cells, PBMC = peripheral blood mononuclear cells. Seventeen placenta samples were originally included, but one sample was excluded later on due to low RNA concentration. Fourteen CBMC samples with paired placental and/or maternal PBMC samples and one CBMC sample without paired placenta and maternal PBMC sample were included. 
